

**PROPOSED CLAIMS**

Claim 1. A method for treating prostate cancer, comprising administering to a patient having prostate cancer a conjugate comprising bismuth-213 or actinium-225 and an antibody specific for prostate cancer cells.

Claim 7. The method of claim 1, wherein the conjugate is administered at a dose from about 0.1 mg/m<sup>2</sup> to about 10 mg/m<sup>2</sup>.

Claim 23. The method of claim 1, wherein the specific activity of the bismuth-213 conjugate is about 20 mCi/mg or about 30 mCi/mg.

Claim 24. The method of claim 1, wherein the conjugate is administered intravenously.

Claim 25. The method of claim 1, wherein the specific activity of the actinium-225 conjugate is about 0.1 mCi/mg to about 0.15 mCi/mg.